close
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Moderna, Inc. - Common Stock (NQ:MRNA)

42.83 +0.60 (+1.42%)
Streaming Delayed Price Updated: 11:40 AM EST, Feb 17, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Moderna, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
17 18 Next >
News headline image
Pfizer's chaotic year wraps up with plunging stock, grim guidance
Pfizer's tumultuous 2023 included a 41.84% stock plunge as revenue from Covid drugs fell. Disappointing 2024 guidance resulted in analysts slashing targets. 
Via MarketBeat
News headline image
Moderna to Present at the 42nd Annual J.P. Morgan Healthcare Conference
Via ACCESSWIRE
News headline image
Moderna Announces New England Journal of Medicine Publication of Pivotal Phase 3 Clinical Safety and Efficacy Data For MRNA-1345, The Company’s Investigational Respiratory Syncytial Virus (RSV) Vaccine
Via ACCESSWIRE
News headline image
Moderna And Merck Announce mRNA-4157 (V940) In Combination with Keytruda(R) (Pembrolizumab) Demonstrated Continued Improvement in Recurrence-Free Survival and Distant Metastasis-Free Survival in Patients with High-Risk Stage III/IV Melanoma Following
Via ACCESSWIRE
News headline image
Moderna Announces Changes to Commercial Organization to Prepare for Multiple Product Launches in 2024 and 2025
Via ACCESSWIRE
News headline image
Moderna to Present at Upcoming Conferences in November 2023
Via ACCESSWIRE
News headline image
Moderna Highlights its Digital and AI Strategy and Progress at Second Digital Investor Event
Via ACCESSWIRE
News headline image
Moderna Tops BioSpace’s Best Places to Work Ranking for Third Consecutive Year
Via ACCESSWIRE
News headline image
Merck and Moderna Initiate INTerpath-002, a Phase 3 Study Evaluating V940 (mRNA-4157) in Combination with KEYTRUDA® (pembrolizumab) for Adjuvant Treatment of Patients with Certain Types of Resected Non-Small Cell Lung Cancer
From Merck & Co., Inc.
Via Business Wire
News headline image
Moderna Reviews its Environmental, Social and Governance (ESG) Progress and Ambitions at Second ESG Investor Event
Via ACCESSWIRE
News headline image
Upwork underscores the strength of the AI gig economy
Upwork has been pursuing its goal of being the world's preeminent destination for artificial intelligence (AI) related talent and freelancers 
Via MarketBeat
Topics Artificial Intelligence
News headline image
Moderna to Host Second Environmental, Social and Governance (ESG) Investor Event on December 7th, 2023
Via ACCESSWIRE
News headline image
Moderna Reports Third Quarter 2023 Financial Results and Provides Business Updates
Via ACCESSWIRE
News headline image
Moderna Announces First Participant Dosed in Phase 3 Study of mRNA-1083, a Combination Vaccine Against Influenza and COVID-19
Via ACCESSWIRE
News headline image
Moderna to Host Second Digital Investor Event on November 8th, 2023
Via ACCESSWIRE
News headline image
CEPI and Moderna Harness mRNA Technology to Advance 100 Days Mission
Via ACCESSWIRE
News headline image
Moderna Named a Top Employer by Science for Ninth Consecutive Year
Via ACCESSWIRE
News headline image
Moderna to Report Third Quarter 2023 Financial Results on Thursday, November 2, 2023
Via ACCESSWIRE
News headline image
3 Undervalued Healthcare Stocks to Watch as Sector Struggles
As the healthcare sector slumps, several major stocks, including Zimmer Biomet, Moderna, and Illumina, appear undervalued in contrast to their intrinsic worth. 
Via MarketBeat
News headline image
Moderna Announces Positive Phase 1/2 Data from mRNA-1083, the Company's Combination Vaccine Against Influenza and COVID-19
Via ACCESSWIRE
Moderna Inc. (NASDAQ: MRNA) Making Surprising Moves in Wednesday Session
Via Investor Brand Network
News headline image
Moderna Receives U.S. FDA Approval for Updated COVID-19 Vaccine
Via ACCESSWIRE
News headline image
Moderna to Host Investor Event - R&D Day and Business Updates
Via ACCESSWIRE
News headline image
Moderna Recommends Shareholders Reject Amended “Mini-Tender” Offer by TRC Capital Investment Corporation
Via ACCESSWIRE
News headline image
EMA Committee for Medicinal Products for Human Use Adopts Positive Opinion Recommending Authorization of Moderna’s Updated Covid-19 Vaccine in The European Union
Via ACCESSWIRE
News headline image
Moderna Expands the Field of mRNA Medicine with Positive Clinical Results Across Cancer, Rare Disease, and Infectious Disease
Via ACCESSWIRE
News headline image
Moderna and Immatics Announce Strategic Multi-Platform Collaboration to Develop Innovative Oncology Therapeutics
Via ACCESSWIRE
News headline image
Moderna Recommends Shareholders Reject “Mini-Tender” Offer by TRC Capital Investment Corporation
Via ACCESSWIRE
News headline image
Moderna to Participate at Morgan Stanley 21st Annual Global Healthcare Conference
Via ACCESSWIRE
News headline image
Moderna Clinical Trial Data Confirm Its Updated Covid-19 Vaccine Generates Strong Immune Response in Humans Against BA.2.86
Via ACCESSWIRE
< Previous 1 2 3 4 5 6 7 8 9
...
17 18 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Starting at $3.75/week.

Subscribe Today